Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019163 (
hepatitis B
)
38,309
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Determination of the amino acid sequence of the immunogenic polypeptides of
hepatitis B
surface antigen may not only permit molecular localization of the distinct determinants a, d, and y but may also lead to the synthesis of a hapten useful in prophylactic immunization against
hepatitis B
virus infection. For this purpose, purified monotypic
hepatitis B
surface antigen of adw subtype was resolved into equal amounts of two major polypeptides (22,000 and 28,000 daltons) and up to six other minor polypeptides by polyacrylamide gel electrophoresis. With the periodate staining reaction, only the 28,000-dalton polypeptide stained as a glycoprotein. Guinea pigs immunized with the 22,000-dalton polypeptide produced potent antisera against determinants a and d, but the 28,000-dalton glycoprotein did not induce a response. Both polypeptides isolated by preparative polyacrylamide gel electrophoresis showed amino acid composition identical with that of the intact antigen. For both polypeptides, hydrazinolysis gave Ile as the carboxyterminus, and carboxypeptidase A digestion gave the same terminal sequence, Val-Tyr-Ile. Both peptides also yielded an identical sequence of amino acids in nine steps of Edman degradation--Met-Glu-Asn-Ile-Thr-Ser(Cys)-
Gly
-Phe-Leu. Our data suggest that
hepatitis B
surface antigen contains a single major immunogenic 22,000-dalton polypeptide component, part of which is modified by the addition of carbohydrate to give rise to the glycopeptide of apparent molecular weight 28,000.
...
PMID:Partial amino acid sequence of two major component polypeptides of hepatitis B surface antigen. 26 93
A variant of
hepatitis B
virus (HBV) having a specific mutation within the S gene has been found to infect vaccinees. To know whether similar variants were involved in Japan, we analyzed two cases of maternal transmission of HBV in infants immunized with
hepatitis B
immune globulin and
hepatitis B
vaccine. DNA clones of HBV S genes were propagated from patients and family members and sequenced. In one family, the DNA clones from the baby patient had a
Gly
-to-Arg mutation at the 145th codon of the S gene, whereas those from her mother had no such mutations. In the other family, all the DNA clones obtained from the two infected children had the 145th codon intact, but they had a missense mutation at the 126th codon of the S gene, causing an amino acid substitution of Asn for Thr or Ile. This same mutation was observed in 12 of 17 clones of DNA obtained from their mother. In comparison with the wild type HBV-derived
hepatitis B
surface antigen, the two types of S gene mutations, either at the 145th or the 126th codon, were associated with a significant decrease in the antigenicity of some determinants on the
hepatitis B
surface antigen, measured by MAb. Amino acid substitution at these sites, therefore, would have induced the escape from conventional vaccines that were S gene products of wild type HBV and also from
hepatitis B
immune globulin, whose main components were probably also antibodies against the S gene products expressed by wild type HBV.
...
PMID:Mutations within the S gene of hepatitis B virus transmitted from mothers to babies immunized with hepatitis B immune globulin and vaccine. 138 17
Amino acid residues 101 to 180 of
hepatitis B
surface antigen (HBsAg) were predicted by sequencing the corresponding part of the S gene of
hepatitis B
virus (HBV) DNA in 46 HBsAg-positive sera, which had been subtyped by immunodiffusion with respect to d/y, w/r, w1 to w4 and q. The sequences of the nine different HBV serotypes defined by these specificities were found to be homogeneous proving that they represent consistent variations of HBV at the genomic level. Residue 127 was found to be important as were Pro, Thr and Leu for w1/w2, w3 and w4, respectively. Five residues were found to differ between ayw1 and ayw2. These were at positions 134 (Phe instead of Tyr), 143 (Thr instead of Ser), 159 (Ala instead of
Gly
), 161 (Tyr instead of Phe) and 168 (Val instead of Ala). However, all these residues were shared by ayw1 and adw2, implying that Arg122 was also important for w1 expression. All genomes expressing r, apart from one ayr strain, had an Ile126, which might explain the pseudo-allelism of w1 to w4 in relation to r, since this substitution might influence the w epitope. There were two regions where adw4q- and adrq- differed from all the q+ subtypes. These were located at residues 158 and 159, and at residues 177 and 178, where both the q- subtypes had amino acid substitutions in adjacent positions. The mapping of the epitopes defining these antigenic specificities will help to link information on the world-wide distribution of HBsAg subtypes to future molecular epidemiology with regard to HBV.
...
PMID:Molecular basis of hepatitis B virus serotype variations within the four major subtypes. 146 53
The X protein of
hepatitis B
virus (HBV) consists of 154 amino acids and trans-activates various cellular and viral promoters and enhancers. To investigate the essential amino acid sequences of X protein for trans-activation function, various mutations were introduced into the X open reading frame and analysed for trans-activation activity by chloramphenicol acetyltransferase assay. The amino acid sequences 46-52 (especially Pro-46, His-49 and His-52), 61-69 (especially Cys-61,
Gly
-67 to Pro-68 and Cys-69) and 132-139 (especially Phe-132, Cys-137 and His-139) of HBV X protein were found to be essential for the trans-activation function. These three sequences are included in the conserved amino acid sequences among hepadna virus X proteins. The first one could form a domain-like structure characteristic of histidine/aspartic acid requirement. The second and the third are homologous to the Kunitz domain of Kunitz-type serine protease inhibitors. The amino acids 5-27 region was found to make no positive contribution to the trans-activation function like the last 12 amino acids in the carboxy-terminal region [Takada, S. & Koike, K. (1990). Proc. Natl. Acad. Sci. USA, 87, 5628-5632]. From these findings, the trans-activation function of X protein appears to be dependent on at least two types of domain-like structures.
...
PMID:Identification of three essential regions of hepatitis B virus X protein for trans-activation function. 154 57
Two determinants of
hepatitis B
surface Ag (HBsAg), identified by mAb raised against polypeptide components, were characterized immunochemically. One was expressed on HBsAg irrespective of the four major subtypes, i.e., adw, adr, ayw, and ayr, whereas the other was subtypic but not identical to any of d, y, w, and r determinants. The common determinant was generated by a synthetic pentadecapeptide with a sequence of Thr-Thr-Ser-Thr-
Gly
-Pro-Cys-Lys-Thr-Cys-Thr-Ile-Pro-Ala-Gln representing amino acids 115-129 of the S gene product, and detected invariably in 366 HBsAg samples in sera from asymptomatic carriers in Japan. The activity of the S gene product, as well as the peptide (115-129), to bind with the mAb was not affected by alkylation alone, but was completely lost after reductive alkylation. The antigenic activity was lost when the S gene product was severed between Lys122 and Thr123 by trypsin. A microconformation maintained by the -Cys121-Cys124 bond, therefore, would be required for the common determinant. The other mAb identified an epitope of HBsAg that was mimicked by a synthetic tetradecapeptide with a sequence of Thr-Cys-Thr-Ile-Pro-Ala-Gln-
Gly
-Thr-Ser-Met-Phe-Pro-Ser, representing amino acids 123-136 of the S gene product. Among 16 HBsAg samples with known S gene sequences, 5 with Ile126 possessed this subtypic determinant, but the remaining 11 with Thr126 did not. The 5
hepatitis B
virus genomes encoding the subtypic determinant differed less than 5.6% from each other in the entire nucleotide sequence, but by 8.0% or more from any of the other 11 genomes without the capacity to encode it.
...
PMID:Synthetic oligopeptides bearing a common or subtypic determinant of hepatitis B surface antigen. 169 80
Epitopes defined by monoclonal antibodies (mAb) specific for the Bordetella pertussis outer membrane protein P.69 (pertactin) were mapped using a series of amino- and carboxy-terminal deletion mutants expressed in Escherichia coli. mAb were found to bind predominantly to a region of pertactin spanning a (Pro-Gln-Pro)5 repeat motif and one mAb was found to bind to another region spanning a (
Gly
-
Gly
-Xaa-Xaa-Pro)5 repeat motif. To localize further the mAb-binding sites, a panel of synthetic peptides, a series of 94 overlapping hexameric peptides, and a P.69 30-amino acid fusion to a
hepatitis B
core protein (HBcAg-69), were synthesized. This combined approach has identified the binding site for the mAb BBO5: Pro-Gly-Pro-Gln-Pro-Pro; mAb BBO7, E4A8 and E4D7: Ala-Pro-Gln-Pro-Pro-Ala-
Gly
-Arg; and mAb BPE3: Thr-Leu-Trp-Tyr-Ala-Glu-Ser-Asn-Ala-Leu-Ser-Lys-Arg. We have used a non-lethal murine respiratory model of B. pertussis infection to investigate the ability of a peptide containing the epitope of the mAb BBO5 to elicit protective immunity. Immunization of mice with the HBcAg-69 protein prevented growth of B. pertussis in the lungs compared to mice receiving HBcAg alone, and protection correlated with high titers of anti-P.69 antibodies.
...
PMID:Identification and characterization of a protective immunodominant B cell epitope of pertactin (P.69) from Bordetella pertussis. 170 65
Fragments of
hepatitis B
virus envelope proteins corresponding to the parts of the pre-S domain were synthesised and immobilized on the carriers with low own immunogenicity. The highest stimulation of the antibody production was observed for the antigens immobilized on microspherical carriers or gelatin modified by H-
Gly
-Tyr-OH. Among peptides used for immunization, pre-S fragment 134-144, conjugated with microspherical carrier, proved to be the most active.
...
PMID:[Study of the antigenic structure of hepatitis B virus proteins. I. Synthesis of pre-S fragments of hepatitis B virus proteins and their immunogenicity]. 234 83
The capsid protein of
hepatitis B
virus (P19) is made of 183 amino acids and carries the antigenic sites of
hepatitis B
core antigen (HBcAg) and
hepatitis B
e antigen (HBeAg) on the amino-terminal domain. The carboxyl-terminal domain of P19 (amino acids 150-183) is arginine-rich (47%) and faces the interior of the nucleocapsid for the binding with DNA. Monoclonal antibody was raised against an antigenic site on this protamine-like region of P19, which was distinct from HBcAg or HBeAg sites, and the novel antigenic site(s) was provisionally designated as
hepatitis B
inner core antigen (HBicAg). When P19 in a low concn (150 ng/ml) was immobilized on the solid surface, HBicAg sites were preserved, while HBcAg or HBcAg sites were no longer available on it. This allowed the detection of antibodies against HBicAg (anti-HBic), by sandwiching them between immobilized P19 and anti-IgG labeled with horseradish peroxidase. Anti-HBic was detected in sera from HBsAg carriers, typically those seropositive for antibody to HBeAg. A synthetic arginine-rich decapeptide, with a sequence of Arg-Arg-Arg-
Gly
-Arg-Ser-Pro-Arg-Arg-Arg, representing amino acids 150-159 of P19 and conserved in the majority of reported
hepatitis B
virus, absorbed the activity to bind with P19 in seven (44%) out of 16 sera containing anti-HBic. These results indicate that the decapeptide carries an HBicAg epitope and the remaining amino acid sequence of the arginine-rich carboxyl terminal domain (160-183) may be responsible for the other HBicAg epitopes.
...
PMID:Antigenic sites on the arginine-rich carboxyl-terminal domain of the capsid protein of hepatitis B virus distinct from hepatitis B core or e antigen. 246 50
The sequence of the preS1 region of the
hepatitis B
virus (HBV) envelope (env) proteins contains a dominant binding site for hepatocytes between residues preS21 and preS47. Purified HBV particles (subtype ad) were used as the immunogen to produce specific monoclonal antibodies (McAbs) against three antigenic regions (S, preS2 and preS1) of the HBV env protein. One McAb, F35.25, was found to be specific for the region 32-53 of the preS1 sequence of HBV, which largely overlapped the hepatocyte receptor binding site. The preS1-specific McAb F35.25 reacted with both HBV subtypes, ad and ay, in radioimmunoassays (RIA) and with the large surface proteins, P39 and GP42, as well as with tryptic fragments preS(1-99/103) and preS(1-113) in Western blotting experiments. This McAb F35.25 preferentially recognized, however, the homologous (ad) preS1 sequence in RIA. The ad/ay amino acid substitution within the hepatocyte receptor binding site at position 35 (
Gly
-Arg) may explain the relative subtype-specificity of F35.25. Finally, the F35.25 epitope was detected in all HBV particles purified from HBeAg-positive human sera, confirming that this preS1 region 32-53 is exposed at the surface of complete virions. Thus, we developed a RIA system allowing us to assess the infectivity of HBV particles by the detection of preS1 sequences associated with the viral hepatocyte receptor. Moreover, it is expected that F35.25 may be a virus-neutralizing antibody by blockage of the attachment of HBV to liver cells.
...
PMID:A monoclonal antibody specific for the hepatocyte receptor binding site on hepatitis B virus. 247 66
The effect on
hepatitis B
surface antigen (HBsAg) of reagents considered specific for each of the amino acid residues, lysine, methionine, cysteine, arginine, tyrosine, tryptophan, and glutamic (aspartic) acid, was studied. Based on the observed alterations of HBsAg antigenicity and the known amino acid sequence of the HBsAg polypeptide, a major antigenic determinant was localized within the sequence: Pro-Ser-Cys-Cys-Cys-Thr-Lys-Pro-Thr(Ser)-Asp-
Gly
-Asn-Cys-Thr-Cys-Ile-Pro-Ile-Pr o-Ser-Ser, corresponding to residues 135-155. The asparagine-linked saccharide chains are not essential for HBsAg antigenicity.
...
PMID:Localization of a hepatitis B surface antigen determinant deduced from results of chemical modifications. 616 48
1
2
3
4
5
Next >>